Comparison of Chemotherapeutic Regimens Frequently Used in
Metastatic Non-squamous NSCLC Treatment

J 2021

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA et. al.

Základní údaje

Originální název

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

Autoři

KREJCI, Daniel (203 Česká republika), Petr OPALKA (203 Česká republika), Jana KREJCI (203 Česká republika), Milada ZEMANOVA (203 Česká republika), Petra ZEMANOVA (203 Česká republika), Juraj KULTAN (203 Česká republika), Ondrej FISCHER (203 Česká republika), Jana SKŘIČKOVÁ (203 Česká republika, domácí), Monika BRATOVÁ (203 Česká republika, domácí), Marketa CERNOVSKA (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Helena ČOUPKOVÁ (203 Česká republika, domácí), Karolína HURDÁLKOVÁ (203 Česká republika), Magda BAŘINOVÁ (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Daniel DOLEZAL (203 Česká republika), Martin SAFANDA (203 Česká republika), Milos PESEK (203 Česká republika) a Martin SVATON (203 Česká republika)

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.435

Kód RIV

RIV/00216224:14110/21:00122867

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/anticanres.15039

UT WoS

000648660800009

Klíčová slova anglicky

NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed

Štítky

14110215, 14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 11. 2021 12:49, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.

Citovat

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Monika BRATOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Helena ČOUPKOVÁ, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ, Leona KOUBKOVA, Daniel DOLEZAL, Martin SAFANDA, Milos PESEK a Martin SVATON. Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, roč. 41, č. 5, s. 2597-2603. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15039.

@article{1803921,
   author = {Krejci, Daniel and Opalka, Petr and Krejci, Jana and Zemanova, Milada and Zemanova, Petra and Kultan, Juraj and Fischer, Ondrej and Skřičková, Jana and Bratová, Monika and Cernovska, Marketa and Hrnciarik, Michal and Čoupková, Helena and Hurdálková, Karolína and Bařinová, Magda and Koubkova, Leona and Dolezal, Daniel and Safanda, Martin and Pesek, Milos and Svaton, Martin},
   article_location = {Athens},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/anticanres.15039},
   keywords = {NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment},
   url = {https://ar.iiarjournals.org/content/41/5/2597},
   volume = {41},
   year = {2021}
}

TY  - JOUR
ID  - 1803921
AU  - Krejci, Daniel - Opalka, Petr - Krejci, Jana - Zemanova, Milada - Zemanova, Petra - Kultan, Juraj - Fischer, Ondrej - Skřičková, Jana - Bratová, Monika - Cernovska, Marketa - Hrnciarik, Michal - Čoupková, Helena - Hurdálková, Karolína - Bařinová, Magda - Koubkova, Leona - Dolezal, Daniel - Safanda, Martin - Pesek, Milos - Svaton, Martin
PY  - 2021
TI  - Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
JF  - Anticancer Research
VL  - 41
IS  - 5
SP  - 2597-2603
EP  - 2597-2603
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - NSCLC
KW  - chemotherapy
KW  - real-world data
KW  - bevacizumab
KW  - pemetrexed
UR  - https://ar.iiarjournals.org/content/41/5/2597
N2  - Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.
ER  -

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Monika BRATOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Helena ČOUPKOVÁ, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ, Leona KOUBKOVA, Daniel DOLEZAL, Martin SAFANDA, Milos PESEK a Martin SVATON. Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, roč.~41, č.~5, s.~2597-2603. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15039.

Podrobný výpis o publikaci